Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Tatva Chintan Pharma Chem Ltd (TATVA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543321 NSE: TATVA Chemicals | Small Cap | Tatva Chintan Pharma Share Price
₹1,750.05 -13.15 (-0.75%)
As on 22-Sep'26 13:07
Tatva Chintan Pharma Chem Ltd (TATVA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543321 NSE: TATVA Chemicals | Small Cap | Tatva Chintan Pharma Share Price
₹1,750.05 -13.15 (-0.75%)
As on 22-Sep'26 13:07
Key Metrics
Valuation Multiples
Market Cap
₹4,124 Cr.
Current Price
₹1,750.1
52-Week Low / High
₹988 / 1,839
TTM EPS
₹22
TTM Sales
₹556 Cr.
Book Value per Share
₹341
P/E Ratio
80.27
Lower than its 5-year historical median
Industry PE
48.1
Price to Book (P/B)
5.17
Higher than its 5-year historical median
Price to Sales (P/S)
7.42
Lower than its 5-year historical median
EV/EBITDA
37.39
Lower than its 5-year historical median
Dividend Yield
0.11%
Profitability Efficiency
Return on Equity (ROE)
5.53%
Underperforms industry median
Return on Capital Employed (ROCE)
7.17%
Underperforms industry median
Return on Assets (ROA)
4.63%
Operating Profit Margin
19%
Net Profit Margin
8.31%
Gross Profit Margin
18.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
35.45%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
171.34%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
636.43%
Asset Quality
Promoter Holding
72.02%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹774 Cr.
Equity
₹23.4 Cr.
Face Value
₹10
All Time Low / High
₹610.00 / 2975.55
Check Before You Invest
Quality
Not GoodValuation
FairCheck Valuation charts
Price Trend
Strong
Is Tatva Chintan Pharma Chem Ltd a good quality company?
Tatva Chintan Pharma Chem Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Tatva Chintan Pharma Chem Ltd performance compare with that of its Peers?
Revenue growth of Tatva Chintan Pharma Chem Ltd vs industry peers?
Tatva Chintan Pharma Chem Ltd revenue CAGR is 10.99%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Tatva Chintan Pharma Chem Ltd?
Promoters hold 72.02% of the Tatva Chintan Pharma Chem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Tatva Chintan Pharma Chem Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -4.76% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Tatva Chintan Pharma Chem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 39% | 20.4% | 22.2% | 26.8% | 27.9% | 25.8% | 7.5% | 6.9% | 0.3% | 6.9% | - |
| Value Creation Index ⓘ | 1.8 | 0.5 | 0.6 | 0.9 | 1.0 | 0.8 | -0.5 | -0.5 | -1.0 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 109 | 129 | 203 | 254 | 291 | 428 | 403 | 379 | 366 | 496 | 534 |
| Sales YoY Gr. | - | 19% | 56.8% | 25.1% | 14.7% | 46.9% | -5.8% | -6% | -3.2% | 35.5% | - |
| Adj EPS ⓘ | 8 | 5.1 | 10.3 | 17.7 | 24.1 | 41.6 | 20.2 | 11.5 | -0.6 | 16 | 19 |
| YoY Gr. | - | -36.4% | 101.2% | 72.8% | 35.7% | 72.8% | -51.4% | -43.4% | -105.2% | NA | - |
| BVPS (₹) ⓘ | 24.7 | 30.2 | 39.6 | 57 | 80.6 | 211.5 | 227.7 | 310.3 | 308.4 | 324.1 | 328.6 |
| Adj Net Profit ⓘ | 16.1 | 10.3 | 20.6 | 35.6 | 48.3 | 92.1 | 44.8 | 26.8 | -1.4 | 37.4 | 44 |
| Cash Flow from Ops. ⓘ | 24.3 | 12.9 | 7.9 | 24.6 | 18.9 | 19.8 | 23.7 | 103 | 24 | 29.2 | - |
| Debt/CF from Ops. ⓘ | 1.9 | 4.4 | 9.8 | 3.7 | 4.8 | 6.1 | 7.2 | 0.1 | 1.5 | 4.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 18.4% | 11.3% | 7.2% | 35.5% | ||||
| Adj EPS ⓘ | 8% | -7.9% | -7.5% | NA | ||||
| BVPSⓘ | 33.1% | 32.1% | 12.5% | 5.1% | ||||
| Share Price | - | -5% | 2.6% | 58.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 39.3 | 18.6 | 29.4 | 36.7 | 35 | 29.2 | 9.2 | 4.4 | -0.2 | 5.1 | 5.8 |
| Op. Profit Mgn % ⓘ | 23.7 | 15.9 | 17.1 | 21.1 | 22.5 | 24.8 | 14.3 | 17.7 | 7.1 | 18 | 18.4 |
| Net Profit Mgn % ⓘ | 14.8 | 7.9 | 10.2 | 14 | 16.6 | 21.5 | 11.1 | 7.1 | -0.4 | 7.5 | 8.3 |
| Debt to Equity ⓘ | 0.9 | 0.9 | 1 | 0.8 | 0.6 | 0.3 | 0.3 | 0 | 0.1 | 0.2 | - |
| Working Cap Days ⓘ | 175 | 189 | 152 | 156 | 190 | 199 | 251 | 256 | 247 | 216 | 115 |
| Cash Conv. Cycle ⓘ | 54 | 76 | 72 | 85 | 106 | 117 | 167 | 175 | 172 | 156 | 43 |
Valuation of Tatva Chintan Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 206 | 263 | 300 | 434 | 424 | 394 | 383 | 506 |
| Operating Expenses ⓘ + | 114 | 172 | 208 | 234 | 325 | 363 | 325 | 348 | 412 |
| Operating Profit ⓘ | 21 | 34 | 55 | 67 | 109 | 61 | 68 | 34 | 93 |
| Operating Profit Margin (%) | 15.9% | 16.5% | 21.0% | 22.2% | 25.0% | 14.3% | 17.4% | 9.0% | 18.5% |
| Other Income ⓘ + | 5 | 0 | 1 | 5 | 9 | 6 | 8 | 2 | 4 |
| Interest ⓘ | 3 | 4 | 4 | 4 | 5 | 9 | 7 | 2 | 3 |
| Depreciation ⓘ | 4 | 4 | 5 | 7 | 8 | 10 | 26 | 28 | 37 |
| Profit Before Tax ⓘ | 20 | 27 | 48 | 61 | 104 | 45 | 44 | 8 | 57 |
| Tax ⓘ | 7 | 7 | 10 | 8 | 8 | -1 | 13 | 2 | 15 |
| Profit After Tax | 13 | 21 | 38 | 52 | 96 | 45 | 30 | 6 | 42 |
| PAT Margin (%) | 9.6% | 10.0% | 14.4% | 17.4% | 22.1% | 10.7% | 7.7% | 1.5% | 8.3% |
| Adjusted EPS (₹) | 6.5 | 10.2 | 18.8 | 26.0 | 43.3 | 20.5 | 13.0 | 2.4 | 18.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 19.20% | 4.60% | 9.80% | 15.40% | 41% | 11.10% |
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 62 | 80 | 118 | 166 | 473 | 515 | 737 | 739 | 782 | ||
| Debt + | 56 | 71 | 79 | 76 | 106 | 160 | 11 | 36 | 119 | ||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Trade Payables | 25 | 22 | 32 | 47 | 45 | 32 | 45 | 33 | 58 | ||
| Others Liabilities ⓘ | 4 | 14 | 20 | 36 | 26 | 37 | 14 | 16 | 35 | ||
| Total Liabilities ⓘ | 147 | 188 | 249 | 325 | 649 | 744 | 807 | 824 | 994 | ||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 56 | 67 | 111 | 120 | 160 | 196 | 427 | 529 | 609 | ||
| CWIP ⓘ | 10 | 6 | 5 | 10 | 51 | 231 | 77 | 24 | 25 | ||
| Investments ⓘ | 1 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 4 | ||
| Inventories | 29 | 36 | 64 | 72 | 170 | 162 | 153 | 134 | 196 | ||
| Trade Receivables | 32 | 41 | 50 | 91 | 57 | 84 | 70 | 90 | 119 | ||
| Cash Equivalents | 9 | 16 | 11 | 5 | 177 | 45 | 38 | 14 | 9 | ||
| Others Assets ⓘ | 10 | 22 | 9 | 27 | 35 | 26 | 32 | 33 | 32 | ||
| Total Assets ⓘ | 147 | 188 | 249 | 325 | 649 | 744 | 807 | 824 | 994 | ||
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 7 | 25 | 20 | 20 | 28 | 98 | 25 | 31 |
| Cash Flow From Investing Activity ⓘ + | 0 | -17 | -40 | -21 | -197 | -101 | -121 | -65 | -116 |
| Cash Flow From Financing Activity ⓘ + | 0 | 17 | 10 | -5 | 235 | 38 | 31 | 17 | 79 |
| Net Cash Flow ⓘ | 0 | 8 | -5 | -6 | 59 | -36 | 8 | -24 | -5 |
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 20.9 | 28.95 | 38.29 | 36.85 | 30.01 | 9.21 | 4.85 | 0.77 | 5.53 | |
| ROCE (%) | 19.15 | 22.78 | 28.4 | 28.04 | 25.75 | 8.35 | 7 | 1.19 | 7.17 | |
| Asset Turnover Ratio | 0.92 | 1.23 | 1.21 | 1.05 | 0.89 | 0.61 | 0.51 | 0.47 | 0.56 | |
| PAT to CFO Conversion(x) | 0 | 0.33 | 0.66 | 0.38 | 0.21 | 0.62 | 3.27 | 4.17 | 0.74 | |
| Working Capital Days | ||||||||||
| Receivable Days | 85.30 | 64.50 | 63 | 85.20 | 62 | 60.70 | 71.30 | 75.90 | 75.20 | |
| Inventory Days | 79.50 | 57.60 | 68.70 | 82.30 | 101.80 | 143.20 | 145.80 | 136.60 | 118.90 | |
| Payable Days | 127.90 | 74.80 | 73.90 | 95 | 86.30 | 61.90 | 80.90 | 71.30 | 73.90 | |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Tatva Chintan Pharma Chem Ltd FAQs
The current trading price of Tatva Chintan Pharma on 22-Sep-2026 13:07 is ₹1,750.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Tatva Chintan Pharma stood at ₹4,124.5 Cr
The latest P/E ratio of Tatva Chintan Pharma as of 21-Sep-2026 is 92.91.
The latest P/B ratio of Tatva Chintan Pharma as of 21-Sep-2026 is 5.37.
The 52-week high of Tatva Chintan Pharma is ₹1,838.9 and the 52-week low is ₹988.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tatva Chintan Pharma is ₹534 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Tatva Chintan Pharma Chem Ltd is a below average quality company.
The key valuation ratios of Tatva Chintan Pharma Chem Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Tatva Chintan Pharma Chem Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Tatva Chintan Pharma Chem Ltd
The company is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes. For instance, its SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.
The company continuously strive to improve its processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of its products, it serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from company’s customers in India, it also export its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.
Business area of the company
The company is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.
Awards, accreditations or recognitions
- 2006: Received ISO 9001:2015 certification for manufacturing facility at Ankleshwar.
- 2015: Appreciation certificate from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for Company’s contribution to the revenue and voluntary compliance with tax laws.
- 2016: Accorded the status of a two star export house from the Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India.
- 2017: Received ISO 14001:2015 and BS OHSAS 18001:2007 certification for our manufacturing facility at Ankleshwar.
- 2018: Received ISO 9001: 2015 certification for manufacturing facilities at Ankleshwar and Dahej.
- 2018: Received ISO 14001: 2015 and BS OHSAS 18001:2007 certification for manufacturing facility at Dahej.
- 2019: R&D facility recognized by the Department of Scientific and Industrial Research, Government of India for the purpose of availing customs duty exemption.
- 2020: Received ISO 14001:2015 and 45001:2018 certification for manufacturing facility at Ankleshwar.
Major events and milestones
- 1996: Incorporation of the company.
- 2004: Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at our Ankleshwar Manufacturing Facility.
- 2007: Expansion of manufacturing capacity at Ankleshwar Manufacturing Facility.
- 2011: Commenced commercial manufacturing of SDAs.
- 2013: Attained turnover of Rs 500.00 million.
- 2015: Attained turnover of Rs 1 billion.
- 2015: Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of Company.
- 2015: Set up warehousing facility in Netherlands.
- 2017: Set up Dahej Manufacturing Facility.
- 2018: Set up R&D facility in Vadodara.
- 2019: Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of Company.
- 2020: Completion of ‘Together for Sustainability’ audit.
- 2020: Conversion of Ankleshwar Manufacturing Facility to a ‘zero liquid effluent discharge facility’.
- 2020: Attained total revenue of Rs 2 billion.
- 2020: Increase in manufacturing capacity at our Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of our Company from 160 KL and 10 Assembly Lines to 280 KL and 13 Assembly Lines.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
